The researchers hope that their research could provide more detailed information on the electrical activity of stem cell derived cardiomyocytes. In the longer term, this could facilitate their use in regenerating the damaged hearts of heart attack victims.
"Human embryonic stem cells promise unrivalled opportunities. However, they are difficult, time-consuming and expensive to grow in the lab", Dr. Chris Denning of the University's Wolfson Centre for Stem Cells, Tissue Engineering & Modelling explained. "Our understanding of how to convert them into cardiomyocytes is poor. At the moment we only know how to produce a few million cardiomyocytes, but to treat just one heart attack patient, we may need one billion that all function in the correct way."
To help overcome the many challenges that stem cells bring, Dr. Denning, co-investigator Professor Stephen Hill and their team plan to engineer a novel system for real-time analysis of cardiomyocytes during early development so their properties are better understood.
The team has already demonstrated that sufficient numbers of stem cell-derived cardiomyocytes can be produced for detailed analysis and they plan to use new "electrophysiology" systems to record changes in the cells when cultured. Electrophysiology is the study of cells' electrical properties and this is the first time that the method has been used in the United Kingdom to study stem cell-cardiomyocyte biology.
"This research will enable rapid development of stem cell-derived cardiomyocytes as a tool for understanding the heart and its diseases", stated Dr. Denning. However, he cautioned: "Before we can consider using stem cells to treat heart-attack patients there are many problems which will take many years to solve. We don't yet know how to deliver the cells to a patient's heart and prevent them being washed away so that they actually stay in the heart and both survive and function. It will take many years to overcome these challenges and put stem cell-derived cardiomyocytes into medical usage."
The researchers will also be monitoring how the cells respond to different pharmacological agents in order to improve drug-screening processes and reduce the need for animal testing. "A key part of the project is to monitor the effects of different drugs on the cells. At present, only limited information is available on how they respond to pharmacological or gene modulating agents", stated Dr. Denning.
"Between 1990 and 2001, 8 different drugs were withdrawn from the market in the USA at an estimated cost of $8 billion because they caused unexpected deaths in several hundred patients. Our aim is to reduce such occurrences by having better test methods to test the drugs before they reach the clinic. By studying the drugs' effects on the heart cells in the lab, this could reduce the need for animals in clinical trials", Dr. Denning stated.
The University of Nottingham is Britain's University of the Year. It undertakes world-changing research, provides innovative teaching and a student experience of the highest quality. Its academics have won two Nobel Prizes since 2003. The University is an international institution with campuses in the United Kingdom, Malaysia and China.
The BBSRC is the United Kingdom's funding agency for research in the life sciences. Sponsored by the Government, BBSRC annually invests around GBP 380 million in a wide range of research that makes a significant contribution to the quality of life for British citizens and supports a number of important industrial stakeholders including the agriculture, food, chemical, health care and pharmaceutical sectors.